GlassScriptPhysician profile
Mohamed S Soliman
NPI 1497795207
$3,078.07
in general payments reported to CMS, 2019-2025
28 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $369 · 2021: $25.81 · 2022: $492 · 2023: $428 · 2024: $729 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $856.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Electromed, INC. | $284.36 | 2022-2025 | Smartvest |
| Ethicon INC. | $230.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $220.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $196.58 | 2019-2025 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $173.43 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $170.33 | 2020-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $141.73 | 2022-2025 | Opsumit |
| Abbvie INC. | $136.11 | 2022 | |
| Insmed, INC. | $87.57 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.75 | 2024-2025 | Ofev |
| Mylan Specialty L.P. | $79.87 | 2024 | Yupelri |
| Verona Pharma, INC. | $71.24 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $50.04 | 2024-2025 | Izervay |
| Gilead Sciences, INC. | $47.24 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.86 | 2023 | Sunosi |
| Genzyme Corporation | $30.08 | 2025 | |
| Pulmonx Corporation | $21.85 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $20.57 | 2023 | Xembify |
| Lilly USA, LLC | $19.58 | 2025 | Zepbound |
| Resmed Corp | $17.09 | 2019 | |
| Fisher & Paykel Healthcare INC | $16.70 | 2024 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $15.70 | 2024 | Winrevair |
| Stryker Corporation | $15.40 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Viatris Specialty LLC | $15.15 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $13.99 | 2022 | |
| Pfizer INC. | $13.96 | 2019 | |
| Phadia US INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.